Conference attendees will have the opportunity to hear a case study provided by peer, John Dobak, CEO of DermTech, as he shares his successes and identifies his challenges with market access and adoption. DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. Dermtech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. Uniquely, DermTech collects samples with an adhesive patch, rather than a scalpel, creating a completely non-invasive alternative. DermTech operates a CLIA licensed laboratory located in the company’s La Jolla, CA headquarters.